Paris-Trousseau thrombocytopenia

Paris-Trousseau thrombocytopenia (also known as Paris-Trousseau syndrome or thrombocytopenia-Paris-Trousseau type) is a rare inherited bleeding disorder caused by a hemizygous deletion on chromosome 11q23.3 that encompasses the FLI1 gene, which encodes a transcription factor critical for normal megakaryocyte development. It is typically seen as part of the broader Jacobsen syndrome (11q terminal deletion syndrome), though it can occur in isolation when the deletion is limited to the FLI1 region. The condition is characterized by mild to moderate thrombocytopenia (low platelet count) present from birth, with distinctive abnormal giant alpha-granules visible in a subset of platelets and megakaryocytes on blood smear and bone marrow examination. Affected individuals have dysfunctional platelets that contribute to a bleeding tendency disproportionate to the degree of thrombocytopenia. The primary body system affected is the hematologic system. Key clinical features include neonatal thrombocytopenia that may improve somewhat with age but typically persists, easy bruising, prolonged bleeding from minor cuts or surgical procedures, and petechiae. In the context of Jacobsen syndrome, patients may also exhibit intellectual disability, characteristic facial features, cardiac defects, and other congenital anomalies, but these additional features are attributable to the larger chromosomal deletion rather than to Paris-Trousseau thrombocytopenia specifically. There is no cure for Paris-Trousseau thrombocytopenia. Management is primarily supportive and includes avoidance of antiplatelet medications (such as aspirin and NSAIDs), precautionary measures before surgical or dental procedures, and platelet transfusions when clinically significant bleeding occurs or prior to invasive procedures. Desmopressin (DDAVP) may be considered in some cases, though its efficacy is variable. Genetic counseling is recommended for affected families. Long-term prognosis for the thrombocytopenia component is generally favorable, as the bleeding tendency is usually mild, though careful monitoring and anticipatory management remain important throughout life.

Common questions about Paris-Trousseau thrombocytopenia